J. Safra Sarasin Holding AG Decreases Stock Position in Cytokinetics, Incorporated $CYTK

Posted by Brian Himes on Jul 16th, 2026

J. Safra Sarasin Holding AG lessened its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 63.1% in the 1st quarter, Holdings Channel reports. The firm owned 8,634 shares of the biopharmaceutical company’s stock after selling 14,736 shares during the period. J. Safra Sarasin Holding AG’s holdings in Cytokinetics were worth $569,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Bank of Montreal Can boosted its stake in Cytokinetics by 1.2% during the fourth quarter. Bank of Montreal Can now owns 13,292 shares of the biopharmaceutical company’s stock valued at $845,000 after buying an additional 160 shares during the last quarter. Kennedy Capital Management LLC increased its stake in Cytokinetics by 1.2% in the 4th quarter. Kennedy Capital Management LLC now owns 13,183 shares of the biopharmaceutical company’s stock worth $838,000 after acquiring an additional 162 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in Cytokinetics by 46.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 171 shares during the last quarter. Vident Advisory LLC raised its holdings in shares of Cytokinetics by 1.4% during the 4th quarter. Vident Advisory LLC now owns 16,455 shares of the biopharmaceutical company’s stock worth $1,046,000 after acquiring an additional 234 shares in the last quarter. Finally, CIBC Private Wealth Group LLC raised its holdings in shares of Cytokinetics by 6.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 3,723 shares of the biopharmaceutical company’s stock worth $237,000 after acquiring an additional 239 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on CYTK shares. Needham & Company LLC reissued a “buy” rating and issued a $102.00 target price on shares of Cytokinetics in a report on Wednesday, June 17th. Truist Financial set a $106.00 price objective on shares of Cytokinetics in a research report on Tuesday, May 5th. Stifel Nicolaus lifted their price objective on shares of Cytokinetics from $98.00 to $108.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Wells Fargo & Company boosted their target price on shares of Cytokinetics from $95.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Finally, Royal Bank Of Canada decreased their target price on shares of Cytokinetics from $119.00 to $117.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 7th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Cytokinetics currently has an average rating of “Moderate Buy” and a consensus price target of $99.90.

Read Our Latest Research Report on Cytokinetics

Insider Activity

In related news, EVP Andrew Callos sold 15,857 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $65.00, for a total transaction of $1,030,705.00. Following the transaction, the executive vice president directly owned 58,555 shares in the company, valued at approximately $3,806,075. This represents a 21.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $77.21, for a total transaction of $579,075.00. Following the completion of the sale, the chief executive officer directly owned 392,830 shares of the company’s stock, valued at approximately $30,330,404.30. The trade was a 1.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 135,536 shares of company stock worth $10,046,609 over the last quarter. 2.60% of the stock is currently owned by insiders.

Cytokinetics Stock Performance

NASDAQ:CYTK opened at $82.62 on Thursday. The firm has a market capitalization of $10.28 billion, a PE ratio of -12.08 and a beta of 0.42. The stock’s fifty day moving average is $77.87 and its 200 day moving average is $68.98. Cytokinetics, Incorporated has a fifty-two week low of $32.89 and a fifty-two week high of $88.31.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.67). The firm had revenue of $19.36 million for the quarter, compared to the consensus estimate of $8.52 million. The company’s revenue was up 1112.5% on a year-over-year basis. During the same quarter last year, the firm earned ($1.36) EPS. Equities analysts forecast that Cytokinetics, Incorporated will post -6.22 EPS for the current year.

About Cytokinetics

(Free Report)

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.